Dr. Marc S Sabatine MD, Boston, Chairman of TIMI Study Group and Professor, Harvard Medical School, describes the very compelling results of OSLER 1 and 2 studies with evolocumab and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction.
 

News • 16-3-2015

PCSK9 inhibitor halves CV endpoints after a year of treatment

ACC 2015 PCSK9 inhibition with evolocumab halves the number of major CV outcomes in the open label OSLER extension programme. Treatment with evolocumab was safe, also at very low LDL-c levels.

3 minute education • 16-3-2015, ACC 2015, San Diego, Prof.dr. John Kastelein

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

ACC 2015 Prof. John Kastelein, Amsterdam, comments on the results of the OSLER program with PCSK9 inhibitor evolocumab and provides a perspective on the potential of PCSK9 inhibitors.